Related Experiment Video

Updated: Feb 13, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.9K

The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors

Andreea Elena Cîrstea1, Alex Emilian Stepan, Claudiu Mărgăritescu

  • 1Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania; astepan76@yahoo.com.

Romanian Journal of Morphology and Embryology = Revue Roumaine De Morphologie Et Embryologie
|March 21, 2018
PubMed

Insights

Epidermal growth factor (EGF) receptor expression is elevated in high-grade ovarian cancers and advanced stages. This suggests EGF receptors are potential therapeutic targets for ovarian serous tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pathology

Background:

  • Epidermal growth factor (EGF) receptors are frequently expressed in human carcinomas.
  • These receptors are established targets for cancer therapeutics.
  • Understanding their expression in ovarian tumors is crucial for treatment strategies.

Purpose of the Study:

  • To analyze the immunoexpression of EGFR, HER2, and HER3 in ovarian serous tumors.
  • To correlate receptor expression with tumor grade and stage.
  • To evaluate the EGF receptor system as a potential therapeutic target in ovarian cancer.

Main Methods:

  • Immunoexpression analysis of EGFR, HER2, and HER3 in 41 ovarian serous tumors.
  • Quantification using Final Staining Score (FSS), considering cell labeling and reaction intensity.
  • Statistical analysis to compare expression levels across different tumor grades and stages.

Main Results:

  • Significantly higher FSS values for all EGF receptors in high-grade serous carcinomas compared to low-grade and borderline tumors.
  • Elevated FSS values in advanced stage ovarian tumors versus initial stages.
  • Positive linear correlations observed between the expression levels of EGFR, HER2, and HER3.

Conclusions:

  • EGFR, HER2, and HER3 immunoexpression correlates with tumor subtype, grade, and stage in ovarian serous tumors.
  • The EGF receptor system represents a promising therapeutic target for ovarian serous tumors.
  • Further investigation into targeting these receptors may lead to improved treatment outcomes.

More Related Videos

Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids07:19

Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids

Published on: January 6, 2023

5.4K
In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

14.3K

Related Concept Videos

Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
4.2K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.0K